tbuckley/cabot-search huggingface dataset:
Repeat biopsy outcomes and change in QOL status at 1 year after active surveillance: Results from a Japanese multicenter prospective study and the PRIAS-JAPAN.
Authors: Mikio Sugimoto, Hiromi Hirama, Yoshiyuki Kakehi, Akito Yamaguchi, Hirofumi Koga, Katsuyoshi Hashine, Shin Egawa, Jun Miki, Nobuo Shinohara, Satoru Maruyama
Journal: Journal of Clinical Oncology (2012)

e15127 Background: In Japan, two prospective multicenter active surveillance (AS) studies are under investigation. The 1 st is a prospective Japanese AS study that has been carried out in favorable risk prostate cancer since 2002. The 2 nd is the PRIAS-JAPAN; 30 institutions in Japan have been participating into the Prostate cancer Research International: Active Surveillance (PRIAS) study as the PRIAS-JAPAN since 2010. The objective of this study is to evaluate the outcomes of 1-year after AS including prostate re-biopsy and the change in QOL status using the two Japanese prospective cohorts. Methods: 134 patients with biopsy proven favorable risk prostate cancer were enrolled into study between January 2002 and December 2003. Triggers to start curable treatment were PSADT of 2 years or shorter or pathological progression at 1-year re-biopsy. AS remaining rate in 33.2% (median observation period: 78 months). On the other hand, PRIAS-JAPAN study was started since January 2010. Until December 2011, 189 patients were enrolled. 1-year after re-biopsy was recommended to all participants and QOL was assessed at enrollment and at 1-year after AS in both studies with Japanese version SF-36 and SF-8 respectively. Results: In the Japanese AS study, 64 patients who underwent re-biopsy, 42 met the pathological selection criteria again. Reclassification rate was 34.4%. In PRIAS-JAPAN, reclassification rate was 28% (p=0.467). There was no predictive parameter for reclassification in the Japanese AS study. On the other hand, number of positive cores was a significant predictive parameter for reclassification in PRIAS-Japan. Almost all domains of QOL at enrollment revealed better QOL than Norm-based Scoring (NBS). At 1-year after AS, there was no significant change and favorable QOL was maintained in both study. Conclusions: Instead of the time difference between the 2 studies was approximately 10 years, reclassification rate for the current AS cohort (PRIAS-J) was comparable or even lower than the former cohort. Health-related QOL of the Japanese patients who opted AS as an initial treatment was better than NBS and it has been maintained 1-year after AS.
춘계학술대회 발표 : 포스터전시 ; 사구체 신염이 병발된 간경변 환자에서 발생한 이뇨제 난치성 복수를 TIPS로 치료한 1예
Authors: 양병윤, 정준오, 서승오, 안석진, 김은실, 박상준, 김윤권, 김소연, 김영중, 조민구, 허헌
Journal: Clinical and Molecular Hepatology (2006)
Association of Statin Use With Risk of Back Disorder Diagnoses
Authors: Una E. Makris, Carlos A. Alvarez, Wei Wei, Eric M. Mortensen, Ishak A. Mansi
Journal: JAMA Internal Medicine (2017)

Association of Statin Use With Risk of Back Disorder DiagnosesBack pain results in tremendous disability and cost; therefore, understanding predisposing or protective factors deserves attention.Statins are widely used, but there is no consensus on whether statins are protective 1 of or deleterious 2-4 to musculoskeletal conditions.A previously published propensity score (PS)-matched study of statin users and nonusers found an association between statin use and increased risk of use-related injury and arthropathies. 2 Scarce data exist on the association of statins with back pain. 3,4 Because statins may increase vulnerability to myalgias and contribute to the myopathic component often experienced with back pain, the objective of this study was to examine the association of statin use with the risk of back disorder diagnoses.Our a priori hypothesis was that statin use would be associated with back disorders, including spondylosis and intervertebral disc disorders.
Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus.
Authors: Olivia Hentic, Chantal Dreyer, Magaly Zappa, Pascal Hammel, Cristian Mateescu, Mohamed Bouattour, Sandrine J. Faivre, Philippe Ruszniewski, Eric Raymond
Journal: Journal of Clinical Oncology (2012)

e14660 Background: Despite low response rate by RECIST, sunitinib and everolimus improved the progression-free survival of patients (pts) with well-differentiated pNET in two large phase III controlled trials. RECIST being a poor surrogate endpoint for PFS, this study aimed evaluating the value of CHOI criteria in PNET pts. Methods: Data for this analysis were collected from pts with well-differentiated PNET treated consecutively with sunitinib or everolimus in our center between 10-2006 and 11-2010. All pts had tumor progression within 12 months (m) prior to treatment. Pts were considered evaluable if CT-scans were performed within 6 weeks prior treatment and &lt;3 months following treatment initiation. A radiologist blinded for clinical data evaluated responses according to RECIST and CHOI criteria. Best responses were correlated with Kaplan Meier estimates of time-to-progression (TTP) and overall survival (OS). Results: A total of 25 pts were treated with either sunitinib or everolimus. Among them, three pts were evaluated using MRI and thus were not evaluable in this study. Twelve pts received sunitinib and ten pts were treated with everolimus (Male/female: 8/14, median age: 57, range 38-76). All pts had tumor progression within 12 m prior to sunitinib or everolimus. Pts were either treated in 1 st line (n=6), 2 nd line (n=9), 3 rd line (n=7) or 4 th line (n=1) after cytotoxic chemotherapy. At the first CT-scan evaluation, 2 pts presented a partial response (PR), 18 pts had a stable disease (SD), and 2 pts had a progressive disease (PD) by RECIST. Using CHOI criteria, 11 PR, 8 SD, and 3 PD were observed. Nine of 18 pts (50%) with SD according to RECIST were reallocated to the responders (PR) using CHOI criteria. Median TTP and OS for all pts were 14.0 m and 35.8 m, respectively. According to RECIST, TTP was higher in pts with PR+SD compared to PD (14.2m vs 3.3m, p&lt;0.0001). According to CHOI criteria, TTP was 26.1m in pts with PR, 8.7m in pts with SD, and 3.5m in pts with PD (p=0.038). Conclusions: Response byCHOI criteria is a prognostic factor for TTP and may identify among SD pts by RECIST those benefiting the most of targeted therapy.
The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming, and Tumorigenesis
Authors: Issam Aldiri, Beisi Xu, Lu Wang, Xiang Chen, Daniel Hiler, Lyra Griffiths, Marc Valentine, Abbas Shirinifard, Suresh Thiagarajan, Andras Sablauer, Marie-Elizabeth Barabas, Jiakun Zhang, Dianna Johnson, Sharon Frase, Xin Zhou, John Easton, Jinghui Zhang, Elaine R. Mardis, Richard K. Wilson, James R. Downing, Michael A. Dyer
Journal: Neuron (2017)
Validation of a geriatric screening test to detect frailty in elderly cancer patients: Improving the G8 test.
Authors: Aurélie Petit-Monéger, Muriel Rainfray, Pierre Soubeyran, Carine A. Bellera, Simone Mathoulin-Pélissier
Journal: Journal of Clinical Oncology (2015)

e12604 Background: The G8 is a geriatric screening test to identify cancer patients older than 70 years who require comprehensive geriatric assessment (CGA) (Sensitivity (Se) = 76%, Specificity (Sp) = 64%). The main objective of our study was to design and evaluate the performance of alternative tests taking into account other predictive domains for frailty. Methods: We included patients recruited in the original ONCODAGE study between 2008 and 2010 and patients recruited in the Aquitaine Geriatric Oncology cohort. We conducted a literature review to identify factors of frailty in elderly cancer patients. Using a Delphi consensus method, we collected 24 European experts’ opinions to validate the most relevant items to improve the G8. Three alternative G8 tests were created and performance assessed on a development population (ONCODAGE cohort). The highest performing test was then compared to the G8, and validated on both internal validation population (ONCODAGE cohort) and external validation population (Aquitaine Geriatric Oncology cohort). Results: The study population consisted of 1435 patients in the ONCODAGE cohort and 364 patients in the Aquitaine Geriatric Oncology cohort. Twenty-three experts (96%) responded to all three Delphi rounds validating two items available in the ONCODAGE study with a strong consensus (›75%): modification of the threshold for the G8 polypharmacy item to six drugs per day (83%), and replacement of G8 item on neuropsychological problems by four IADL items predictive of incident dementia, creating three modified G8 tests (additional of either item, or both). Only the G8 IADL-modified test (replacement of the G8 neuropsychological item by four IADL items) had better performance than the original G8: Se = 77%, Sp = 67%. This IADL-modified G8 test was validated both on the internal validation population (Se = 78%, Sp = 71%) and on the external validation population (Se = 88%, Sp = 69%). Conclusions: Taking into account items from the IADL predicting incident dementia improves the performance of the G8. We have developed and validated a G8-modified test that is more specific than the G8 to detect frail elderly patients, while still highly sensitive and feasible in less than ten minutes.
The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method
Authors: Valentín García Gutiérrez, María Teresa Gómez-Casares, Jose Manuel Puerta, Juan Manuel Alonso, Santiago Osorio, Juan Carlos Hernández-Boluda, Rosa Collado, Maria Jose Ramirez, Fatima Ibañez, Maria Luisa Martin, Juan Diego Rodriguez, Carolina Martinez-Laperche, Montse Gomez, Viviana Fiallo, Redondo Sara, Alicia Rodriguez, Concepcion Ruiz, Juan Luis Steegmann, Antonio Jiménez-Velasco
Journal: Blood (2016)
Multifunctional Nucleus-targeting Nanoparticles with Ultra-high Gene Transfection Efficiency for <i>In Vivo</i> Gene Therapy
Authors: Ling Li, Xia Li, Yuzhe Wu, Linjiang Song, Xi Yang, Tao He, Ning Wang, Suleixin Yang, Yan Zeng, Qinjie Wu, Zhiyong Qian, Yuquan Wei, Changyang Gong
Journal: Theranostics (2017)

Cancer stem cell-like cells (CSCL) are responsible for tumor recurrence associated with conventional therapy (e.g. surgery, radiation, and chemotherapy). Here, we developed a novel multifunctional nucleus-targeting nanoparticle-based gene delivery system which is capable of targeting and eradicating CSCL. These nanoparticles can facilitate efficient endosomal escape and spontaneously penetrate into nucleus without additional nuclear localization signal. They also induced extremely high gene transfection efficiency (>95%) even in culture medium containing 30% serum, which significantly surpassed that of some commercial transfection reagents, such as Lipofectamine 2000 and Lipofectamine 3000 etc. Especially, when loaded with the TRAIL gene, this system mediated remarkable depletion of CSCL. Upon systemic administration, the nanoparticles accumulated in tumor sites while sparing the non-cancer tissues and significantly inhibited the growth of tumors with no evident systemic toxicity. Taken together, our results suggest that these novel multifunctional, nucleus-targeting nanoparticles are a very promising in vivo gene delivery system capable of targeting CSCL and represent a new treatment candidate for improving the survival of cancer patients.
Relook endoscopy predicts the development of esophageal and antropyloric stenosis better than immediate endoscopy in patients with caustic ingestion
Authors: Rakesh Kochhar, Munish Ashat, Yalaka Reddy, Narender Dhaka, Manish Manrai, Saroj Sinha, Usha Dutta, Thakur Yadav, Vikas Gupta
Journal: Endoscopy (2017)

Abstract Background and aims Early ( &lt; 24 hours) esophagogastroduodenoscopy (EGD) is used to prognosticate mucosal injury after caustic ingestion. We aimed to compare differences in endoscopic grading on EGDs performed on day 5 and day 1 and to assess the impact of relook endoscopy findings on the development of esophageal and/or antropyloric cicatrization. Patients and methods Consecutive patients admitted within 24 hours of caustic ingestion between 2009 and 2014 underwent EGD and had their mucosal changes graded. Injuries of grade ≤ 2a were classified as mild and ≥ 2b were classified as severe. Patients were followed up for the development of cicatrization and managed per protocol. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and likelihood ratios (LRs) were calculated to compare day 1 and day 5 EGD findings. Results A total of 62 patients (35 men; mean age 33 ± 15) underwent both day 1 and day 5 EGDs. Antropyloric stenosis developed in 16 patients, esophageal strictures in nine, and four had both esophageal and antropyloric strictures. Compared with day 1 EGD, endoscopic grading of severe injury on day 5 had higher specificity (83 % vs. 65 %), higher PPV (60 % vs. 41 %), and higher positive LR (5.65 vs. 2.66) for predicting the development of esophageal stricture. Similarly, day 5 endoscopic grading had higher specificity (95 % vs. 61 %), higher PPV (88 % vs. 54 %), and higher positive LR (16 vs. 2.5) for predicting the development of antropyloric stenosis. Conclusion Endoscopic assessment on day 5 is a better predictor of esophageal and gastric cicatrization than day 1 EGD, which significantly overestimates the grade of injury.
A Brain Network–Based Grading of Psychosis
Authors: Lena Palaniyappan, Kara Dempster, Qiang Luo
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response
Authors: Benjamin M. Larimer, Eric Wehrenberg-Klee, Frank Dubois, Anila Mehta, Taylor Kalomeris, Keith Flaherty, Genevieve Boland, Umar Mahmood
Journal: Cancer Research (2017)

While cancer immunotherapy can produce dramatic responses, only a minority of patients respond to treatment. Reliable response biomarkers are needed to identify responders, and conventional imaging modalities have not proved adequate. Here, we provide a preclinical proof of concept for the use of granzyme B, a downstream effector of tumoral cytotoxic T cells, as an early biomarker for tumors responding to immunotherapy. We designed novel PET imaging probes for the murine and human granzyme B isoforms that specifically and quantitatively bind granzyme B. Immunotherapy-treated mice were imaged prior to therapy-induced tumor volume reduction. Imaging distinguished treated responders from nonresponders with excellent predictive ability. To assess the clinical value of a granzyme B imaging paradigm, biopsy specimens from melanoma patients on checkpoint inhibitor therapy were analyzed. A marked differential in granzyme B expression was observed between treated responders and nonresponders. Additionally, our human probe was able to specifically detect granzyme B expression in human samples, providing a clear candidate for clinical application. Overall, our results suggest granzyme B PET imaging can serve as a quantitatively useful predictive biomarker for efficacious responses to cancer immunotherapy. Cancer Res; 77(9); 2318-27. ©2017 AACR.
THE EFFICACY OF A MOVEMENT CONTROL EXERCISE PROGRAMME TO PREVENT INJURIES IN YOUTH RUGBY: A CLUSTER-RANDOMISED CONTROLLED TRIAL
Authors: Michael Hislop, Keith Stokes, Sean Williams, Carly McKay, Simon Kemp, Mike England, Grant Trewartha
Journal: British Journal of Sports Medicine (2017)

Background Structured pre-activity exercise programmes have demonstrated injury prevention in a variety of settings, but their efficacy is largely unknown in contact-orientated sports. Objective To assess the efficacy of a pre-activity movement control exercise programme to reduce injury risk in youth rugby when compared with a standardised exercise programme. Design Single-blind cluster-randomised controlled trial. Setting Independent schools within England during the 2015/16 playing season. Participants Schools with onsite medical provision were eligible to participate in this trial. 31 schools (intervention, 17 schools, 1,325 players; control, 14 schools, 1,127 players) completed the trial. Interventions Both programmes were completed for 15–20 minutes prior to main sessions, with team coaches acting as delivery agents. The intervention programme combined progressive proprioceptive, resistance, and plyometric activities. The standardised programme combined dynamic stretching, wrestling-based and speed-based activities. Main Outcome Measures Trial-arm comparisons were made across summary measures of time-loss (&gt;24 hours) injuries, with effects analysed through magnitude-based inference against thresholds for the smallest worthwhile effects (RR=0.90 &amp; 1.11). Results 441 time-loss injuries (intervention, 233; control, 208) were reported across 15,953 match exposure-hours (intervention, 9,083 hours; control, 6,870 hours). Intention-to-treat analyses revealed a 15% reduction in overall match injury incidence favouring the intervention (relative risk=0.85, 90% CI 0.61–1.17, unclear effect), whilst reductions were also identified in match concussion incidence (RR=0.71, 0.48–1.05, likely beneficial effect). Per-protocol analyses revealed that completing the intervention programme compared with the control programme an average of 2x/week was associated with a further reduction in overall match injury incidence (RR=0.73, 0.45–1.20, unclear effect), whilst an average use of 3x/week halved overall match injury incidence (RR=0.50, 0.22–1.13, likely beneficial effect). Conclusions This study presents encouraging evidence that using a preventive exercise programme 2–3x/week prior to training and matches can reduce injury risk in youth rugby when compared with a standardised programme.
Clinical trial results of a HER2/neu peptide (E75) vaccine in preventing recurrence in node positive breast cancer patients
Authors: Matthew T. Hueman, Jennifer M. Gurney, Michael M. Woll, Catherine E. Storrer, Lindsay Kotula, Marija Wilson, Kimberly A. Jackson, Craig D. Shriver, Sathibalan Ponniah, George E. Peoples
Journal: Cancer Research (2004)

1416    Introduction:  The E75 peptide is an immunogenic CTL epitope from the HER2/neu protein that is overexpressed in breast cancer (BrCa). We are conducting clinical trials in node-positive (NP) BrCa patients to test the ability of E75 to prevent breast cancer recurrence.  Methods:  34 NP BrCa patients with HER2/neu expressing tumors have been enrolled (14 HLA-A2+ vaccinated and 20 HLA-A2- controls). The first 9 patients were vaccinated with E75 monthly x 6 with 3 dose escalation groups (100, 500, 1000ug) to determine the optimal biological dose (OBD). HLA-A2:Ig dimers loaded with E75 were used with CD8 antibodies to stain peripheral blood cells for the detection of E75 specific CD8 T-cells (E75+CD8) by flow cytometry. DTH to E75 was determined at completion. Clinical recurrences was documented.  Results:  Only 3 patients experienced Grade II toxicity, but 2 patients did not complete the series by choice. Prior to vaccination, E75+CD8 were detected in 6/12 patients ranging from 0.72-2.36%; the rest had  Conclusions:  The E75 vaccine strategy is safe and effective in eliciting an immune response against the E75 epitope of the HER2/neu protein in BrCa patients. In high risk breast cancer patients, the E75 vaccine may prevent and/or prolong time to recurrence.
Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the <scp>ESC</scp> Heart Failure Long‐Term Registry
Authors: Ovidiu Chioncel, Alexandre Mebazaa, Veli‐Pekka Harjola, Andrew J. Coats, Massimo Francesco Piepoli, Maria G. Crespo‐Leiro, Cecile Laroche, Petar M. Seferovic, Stefan D. Anker, Roberto Ferrari, Frank Ruschitzka, Silvia Lopez‐Fernandez, Daniela Miani, Gerasimos Filippatos, Aldo P. Maggioni
Journal: European Journal of Heart Failure (2017)
Movement for Health: stopping the decline by building on bright spots and new evidence
Authors: Steve Aspinall
Journal: British Journal of Sports Medicine (2017)

Gloomy headlines are familiar; according to the WHO, an estimated 3.2 million deaths globally are caused by inactivity. On the other hand, we as health professionals know the solution—regular physical activity of a moderate intensity can also reduce the risk of type 2 diabetes, cardiovascular diseases, breast and colon cancer as well as improving bone and joint health. But the big challenges is how to implement our knowledge and grow our influence.

There is evidence of many very positive steps in the right direction. The fantastic Daily Mile programme gets our children moving whatever the weather and the excellent Movement for Movement global resources are now being used in medical and allied health educational programme ( see page 767 ). Only this morning, the UK’s most popular radio show had the popular activity proponent Professor Greg Whyte discussing activity strategies for the desk-bound office worker.

The BJSM community has contributed a great deal to knowledge in this area, including an expert statement looking at the sedentary office.1 BJSM has published special issues on physical activity and …
Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease
Authors: Natasha M. Rogers, Kedar Ghimire, Maria J. Calzada, Jeffrey S. Isenberg
Journal: Cardiovascular Research (2017)

Matricellular proteins are secreted molecules that have affinities for both extracellular matrix and cell surface receptors. Through interaction with structural proteins and the cells that maintain the matrix these proteins can alter matrix strength. Matricellular proteins exert control on cell activity primarily through engagement of membrane receptors that mediate outside-in signaling. An example of this group is thrombospondin-1 (TSP1), first identified as a component of the secreted product of activated platelets. As a result, TSP1 was initially studied in relation to coagulation, growth factor signaling and angiogenesis. More recently, TSP1 has been found to alter the effects of the gaseous transmitter nitric oxide (NO). This latter capacity has provided motivation to study TSP1 in diseases associated with loss of NO signaling as observed in cardiovascular disease and pulmonary hypertension (PH). PH is characterized by progressive changes in the pulmonary vasculature leading to increased resistance to blood flow and subsequent right heart failure. Studies have linked TSP1 to pre-clinical animal models of PH and more recently to clinical PH. This review will provide analysis of the vascular and non-vascular effects of TSP1 that contribute to PH, the experimental and translational studies that support a role for TSP1 in disease promotion and frame the relevance of these findings to therapeutic strategies.